Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802570 | 0.96 | P4HTM (0.55) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6551669 | 0.92 | LMNA (0.59) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8614184 | 0.86 | PRMT5 (0.54) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6212230 | 0.84 | LMNA (0.50) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL29442816 | 0.83 | MAOB (0.62) | MAOBMAOAALOX5NR4A2 | |
| SCHEMBL21384055 | 0.83 | MAOB (0.62) | MAOBMAOAALOX5NR4A2 | |
| SCHEMBL21464426 | 0.82 | TDP1 (0.50) | P4HTML3MBTL1 | |
| SCHEMBL1259197 | 0.82 | NPC1 (0.55) | MAOBRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL18429718 | 0.82 | APP (0.64) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL4569961 | 0.81 | NPC1 (0.57) | MAOBRAB9AGAAMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116875-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | REGLAGENE INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4673130-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR THE TREATMENT OF HEALTH CONDITIONS | Reglagene, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250091997-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | REGLAGENE, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12215102-B2 | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions | REGLAGENE, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2024213125-A1 | BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF | 南京再明医药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240327398-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR THE TREATMENT OF HEALTH CONDITIONS | REGLAGENE, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| EP-1243268-A1 | MEDICINAL COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1156045-A1 | AMIDE DERIVATIVES AND DRUG COMPOSITIONS | Nippon Shinyaku Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0880501-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028128-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| US-4406907-A | Certain 2,5-disubstituted pyridine derivatives producing β-adrenergic blocking action | SYNTHELABO (FR) | 1983-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091997-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | TUBB3, TUBB1, TUBB6 | P4HTM 4750/4885LMNA 2078/4885CYP1A2 4667/4885 |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | P4HTM 3719/4885LMNA 2607/4885CYP1A2 3406/4885 |
| US-20240327398-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR THE TREATMENT OF HEALTH CONDITIONS | PYGB, FABP7, HCCS | P4HTM 4555/4885LMNA 2736/4885CYP1A2 3964/4885 |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | P4HTM 1425/4885LMNA 4342/4885CYP1A2 28/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | P4HTM 1425/4885LMNA 4342/4885CYP1A2 28/4885 |
| US-20260116875-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | TUBB1, TUBB6, TUBB | P4HTM 4404/4885LMNA 3878/4885CYP1A2 3572/4885 |
| US-12215102-B2 | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions | TUBB3, TUBB1, TUBB6 | P4HTM 4750/4885LMNA 2078/4885CYP1A2 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.